Výsledky vyhledávání

Adherence to different adjuvant endocrine therapies in HR+ HER2-breast cancer and its relation to real-world progression rates

Autor: Ivana Durutovic, Shady Gendy, Deepa Kumar, Elise Amioka

Publikováno v: Journal of Clinical Oncology. 40:e12507-e12507

e12507 Background: Adjuvant hormonal therapy (Adj.) has significantly improved long-term survival of breast cancer (BC) patients with hormone receptor-positive (HR+) disease1. Despite proven efficacy, many breast cancer patients fail to adhere to tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a5ad5a125869901034a92f5e0f23f8c
https://doi.org/10.1200/jco.2022.40.16_suppl.e12507

Zobrazit plný text záznamu

Does order matter? Real-world data on outcomes of successive regimens involving anti-PDx-1 in advanced and metastatic non-small cell lung cancer

Autor: David Hadley, Shady Gendy

Publikováno v: Journal of Clinical Oncology. 39:e21159-e21159

e21159 Background: In 2020, 65% of newly diagnosed advanced (adv)or metastatic (met) NSCLC patients in US started first line (1L) systemic therapy on anti-PDx-1 regimen, 53% of second line (2L). Between broader approvals of anti-PDx-1, increasing use

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0217fb6e6184223bd1bdb290508af55b
https://doi.org/10.1200/jco.2021.39.15_suppl.e21159

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání